EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy

Quan Hong, Hyoungnae Kim, Guang-Yan Cai, Xiang-Mei Chen, John Cijiang He, Kyung Lee

International Journal of Biological Sciences · 03.02.2025 · 21 (4) · 1649-1665

DOI: 10.7150/ijbs.101548 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Biological Sciences, erschienen am 03.02.2025. Verfasst von Quan Hong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, NY, USA. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Signal Transduction, Renal Insufficiency, Chronic, Kidney Diseases. Die Arbeit wurde bisher 75-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of chronic kidney disease (CKD) is increasing worldwide, posing a significant healthcare challenge. Despite the immense burden of CKD, optimal therapies remain limited in impact. Kidney fibrosis is a common mediator of all CKD progression, characterized by excessive extracellular matrix deposition and scarring of kidney parenchyma. Transforming growth factor-β (TGF-β) is a potent pro-fibrotic cytokine that signals through canonical and non-canonical pathways to promote kidney cell damage and fibrosis progression, thus garnering much interest as an optimal therapeutic target for CKD. However, the clinical translation of TGF-β inhibition in CKD and other disease settings has faced substantial challenges, particularly due to the highly pleiotropic effects of TGF-β in organ homeostasis and disease. Here, we review the kidney cell-specific biological effects of TGF-β signaling, discuss the current challenges in therapeutic targeting TGF-β in CKD, and provide the rationale for alternative targeting strategies of TGF-β signaling as potential approaches in CKD therapy. Selective inhibition of TGF-β signaling modulators to fine-tune TGF-β inhibition without a broad blockade may lead to new and safer treatments for CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor betaSignal TransductionRenal Insufficiency, ChronicKidney DiseasesHumansFibrosisAnimalsKidney

Stichwörter der Autor:innen

ALK1ALK5CKDDKDHIPK2Kidney fibrosisLRG1.Smad3TGF-βTGFBR2

Substanzen

Transforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, NY, USA.
  • Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center of Kidney Diseases, Beijing, China.
  • James J. Peters Department of Veterans Affairs Medical Center, Bronx, NY, USA.

Zitieren

APA

Hong, Q., Kim, H., Cai, G. Y., Chen, X. M., He, J. C., & Lee, K. (2025). Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy. International Journal of Biological Sciences, 21(4), 1649-1665. https://doi.org/10.7150/ijbs.101548

Vancouver

Hong Q, Kim H, Cai GY, Chen XM, He JC, Lee K. Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy. International Journal of Biological Sciences. 2025;21(4):1649-1665. doi:10.7150/ijbs.101548

BibTeX
@article{Hong2025,
  author = {Hong, Quan and Kim, Hyoungnae and Cai, Guang-Yan and Chen, Xiang-Mei and He, John Cijiang and Lee, Kyung},
  title = {Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  volume = {21},
  number = {4},
  pages = {1649--1665},
  doi = {10.7150/ijbs.101548}
}
Kostenlos starten →